Jonathan Lim, Erasca CEO (ARCH Venture Partners)
How sub can you subset? Erasca shores up case for testing its two lead candidates in combo
It’s challenging enough to get one cancer drug approved.
But it looks like Erasca is gunning for its two lead candidates in combination — though both …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
